A study aimed to compare corneal topographic and specular microscopic parameters both before and after patients received the ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

Pfizer Inc.'s (NYSE:PFE) COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, Monsanto, in the 1980s. This pioneering work, originally designed to strengthen ...

Bayer has filed patent infringement lawsuits against COVID-19 vaccine makers Pfizer, BioNTech, Moderna, and Johnson & Johnson. The company claims these firms misused mRNA technology pioneered by ...

On August 1, 2025, a UK Court of Appeal upheld the validity of Moderna’s European Patent No. 3,590,949 (“EP’949”) in a dispute with Pfizer and BioNTech. The decision affirmed a July 2024 UK High Court ...

By Blake Brittain Jan 6 (Reuters) - Bayer's Monsanto sued COVID-19 vaccine makers Pfizer, BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology ...